Tango Therapeutics, Inc.
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Tango Therapeutics, Inc.
RECRUITINGPhase 1 / Phase 2NCT06810544
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part...
Sponsor: Tango Therapeutics, Inc.Enrolling: 19113 locations
Non Small Cell Lung CancerGlioma Glioblastoma MultiformeGlioma, Malignant+4
RECRUITINGPhase 1 / Phase 2NCT05732831
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation...
Sponsor: Tango Therapeutics, Inc.Enrolling: 22520 locations
Locally Advanced Solid Tumor